P/B
3,6
ORIC Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
$1.4B
Market Cap • 9/25/2026
2014
(12 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,7
EPS
—
Market Cap
Market Cap
1,4B
EV
1,1B
EV/Revenue
0
EV/EBITDA
-7,1
EV/EBIT
-7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-12,9%
Total Yield
-12,9%
Payout
0%
Retained Earnings
-769,5M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
54,3%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
0,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
11,3%
CAGR Net Income 5Y
9%
CAGR EPS 5Y
-12,9%
CAGR OCF 5Y
13,8%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
13,2
Quick Ratio
12,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!